In patients with diabetes, impaired insulin signalling might lead to chronic subclinical low-grade inflammation via activation of AP-1 and NF-κB leading to a decrease in anti-inflammatory cytokines and to an increase in the pro-inflammatory cytokines TNF-α, IL-6 and IL-1β. The gene discussed is INS; the disease is diabetes mellitus.